Ignite Creation Date:
2025-12-25 @ 2:13 AM
Ignite Modification Date:
2025-12-26 @ 7:11 PM
Study NCT ID:
NCT04811560
Status:
RECRUITING
Last Update Posted:
2025-12-10
First Post:
2021-03-22
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Phase 1/2 Study of Bleximenib in Participants With Acute Leukemia (cAMeLot-1)
Sponsor:
Janssen Research & Development, LLC
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2021-05-19
Start Date Type:
ACTUAL
Primary Completion Date:
2026-02-16
Primary Completion Date Type:
ESTIMATED
Completion Date:
2028-05-26
Completion Date Type:
ESTIMATED
First Submit Date:
2021-03-22
First Submit QC Date:
None
Study First Post Date:
2021-03-23
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-12-04
Last Update Post Date:
2025-12-10
Last Update Post Date Type:
ESTIMATED